/

4DX.AX

4DMEDICAL FPO [4DX]Open

3.79−0.01 −0.39%AUD

ASX · as of Oct 14, 21:27 ET · 20m delay

Open

3.84

Prev close

3.80

Day range

3.683.93

52-week range

1.407.55

Volume

1.87M0.42×

Mkt cap

2.28B

P/E ttm

—

Fwd P/E

-194.10

EPS ttm

-0.3500

Div yield

0.00%

Earnings

—

From 52w high

−49.87%

Price Chart

Yahoo Finance · delayed

4DX.AXOct 15, 2026O 3.84H 3.93L 3.68C 3.79−0.01 (−0.39%)Vol 1.87M

SMA 503.85
SMA 2004.12

1Y change +99.21% since Oct 14, 2025 close547 bars loadedTimes in Australia/SydneyDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

4DX.AX 4DMEDICAL FPO [4DX] · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.18%
1 month: +1.20%
3 months: −0.13%
6 months: −40.86%
Year to date: −3.69%
1 year: +105.71%

Valuation & ownership

Market cap: 2.28B
Enterprise value: 2.19B
P/E (ttm): —
Forward P/E: -194.10
PEG ratio: —
Price / book: 13.28
Price / sales (ttm): 322.69
EV / EBITDA: -39.06
EPS (ttm): -0.3500
EPS (forward): -0.0195
Beta (5y monthly): 1.84
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 602.03M
Float: 505.54M
Short % of float: —
Short ratio (days): —
Held by insiders: 16.58%
Held by institutions: 23.84%
Avg volume (3m): 4.45M
50-day average: 3.87
200-day average: 4.12
52-week change: +105.71%
S&P 500 52-week: +15.71%

Technicals (daily)

RSI (14): 44.8
vs 50-day SMA: −1.79%
vs 200-day SMA: −8.22%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.70%
Realised vol (20d, ann.): 69.2%
From 52-week high: −49.87%
From 52-week low: +170.36%

ANR

Analyst Consensus

3 analysts

Consensus

Hold

3.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

4.37

+15.37% implied

Low 3.00Median 4.10High 6.00

Recommendation trend

Now1 / 1 / 1
1m ago / 1 /

DES

About 4DMEDICAL FPO [4DX]

Yahoo Finance profile

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.

Sector: Healthcare
Industry: Medical Devices
Employees: 181
Headquarters: Carlton, VIC, Australia
Website: 4dmedical.com
Officers: Dr. Andreas Fouras B.E., M.A.I.C.D., Ph.D. Founder, MD, CEO & Director
Mr. Julian Sutton B.Sc., C.F.A. CFO & Executive Director

SEAS

Seasonality · 4DX.AX

2020–2026 · monthly returns

Strongest month Sep +43.26%Weakest month Feb −16.52%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-19.3	26.2	39.0	-27.9	-1.0	14.1	-19.9	-5.8	24.3	-10.9			−3.7%
2025	13.5	-29.4	-29.9	18.5	6.3	-29.4	0.0	137.5	247.4	-12.1	-1.7	129.8	+718.8%
2024	-18.2	13.7	-2.3	-7.7	-1.7	-11.9	-7.7	-8.3	53.4	-21.5	-13.2	4.3	−32.9%
2023	3.6	-9.2	-19.0	165.6	-9.4	-13.0	3.0	-2.9	-32.8	3.3	105.4	-25.1	+70.2%
2022	-18.5	-36.4	21.4	-14.1	-11.6	-8.5	20.3	-4.2	-14.7	11.2	-25.6	-12.5	−68.9%
2021	-9.5	-21.4	-0.6	-8.1	-19.0	-4.3	25.7	3.6	-8.2	-7.5	1.1	-1.5	−44.4%
2020									14.5	35.9	-0.4	5.7	+63.6%

INSD

Insider Activity · 4DX.AX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 18, 2026	Bianchi (Lilian)Non Executive Chairman	—	308.4K	—
Jun 18, 2026	Livingston (John Andrew)Director (Executive)	—	247.6K	—
Jun 18, 2026	Sutton (Julian)Director (Non-Executive)	Purchase at price 3.08 per share.	11.4K	$35.05K
Jun 17, 2026	Sutton (Julian)Director (Non-Executive)	Purchase at price 2.69 per share.	13.1K	$35.07K
Feb 25, 2026	Figlin (Robert Alan)Director (Non-Executive)	—	302.8K	—
Feb 25, 2026	Mcginty (Geraldine Bernadette)Director (Non-Executive)	—	213.5K	—
Jan 20, 2026	Fouras (Andreas)Chief Executive Officer	—	1.59M	—
Jan 20, 2026	Sutton (Julian)Director (Non-Executive)	—	2.00M	—
Jan 14, 2025	Bianchi (Lilian)Non Executive Chairman	—	196.9K	—
Jan 14, 2025	Livingston (John Andrew)Director (Executive)	—	60.1K	—
Jan 14, 2025	Sutton (Julian)Director (Non-Executive)	—	60.1K	—
Jan 13, 2025	Figlin (Robert Alan)Director (Non-Executive)	—	60.1K	—
Jan 13, 2025	Mcginty (Geraldine Bernadette)Director (Non-Executive)	—	137.8K	—

4DX.AX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

4DX.AX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About 4DMEDICAL FPO [4DX]

Seasonality · 4DX.AX

Insider Activity · 4DX.AX

Congress Trades · 4DX.AX

Investors Holding 4DX.AX

Investors Holding 4DX.AX

Congress Trades · 4DX.AX

Insider Activity · 4DX.AX

Seasonality · 4DX.AX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About 4DMEDICAL FPO [4DX]

Financial Snapshot

Earnings & Dividends

News